Targeting the
Impossible

TAREXIS is a biotech company advancing innovative therapeutics through novel target discovery for patients with limited treatment options.

First-in-Class Antibody Therapeutics  ·  A Real-World Evidence Driven Platform
PLATFORM

Proprietary Discovery Platforms

Two integrated platforms systematically narrow the field to high-confidence targets and pre-validate their clinical performance before IND-enabling studies begin.

🔍  Tx-Finder™

Autonomous multi-omics
Analytics Engine

Auto-prioritize best targets from 10,000+ candidates
Multi-omics integration & algorithmic scoring
Multi-dimensional: druggability + market attractiveness
Surface expression, receptor identity, safety profile

4-Step Candidate Filtering Process

Tx-Finder 4-Step Candidate Filtering Process
Tx-Finder™ Dashboard
Tx-Finder dashboard screenshot
🧫  Tx-Verifier™

Patient-Derived Organoid
Based Validation Platform

PDOs from patient-derived clinical samples
Fail-gate strategy: eliminate poor candidates early
Responder profiling & classification
Patient-derived organoid xenograft (PDOX) model
PDO microscopy 1 PDO microscopy 2 PDO microscopy 3

Patient-derived organoids (PDO)

Pipeline
Program Class Indication Modality Stage Partner
TX-101 FIC LSCC · Metastatic Solid Tumors ADC
Discovery
 Undisclosed
TX-102 FIC Solid Tumors ADC
Discovery
 Undisclosed
TX-103 FIC Solid Tumors ADC
Discovery
 Undisclosed
TX-104 FIC Solid Tumors ADC
Discovery
 Undisclosed
TX-201 FIC CRC ADC
Discovery
 —
TX-301 FIC PDAC ADC
Discovery
 —

LSCC: Lung Squamous Cell Carcinoma · CRC: Colorectal Cancer · PDAC: Pancreatic Ductal Adenocarcinoma

Contact
📧
📍
Location
Room 512, 34, Sangwon 12-gil, Seongdong-gu, Seoul, Republic of Korea

Send an Inquiry

Tell us about your interest and we'll be in touch.

Submitting opens your mail app addressed to tarexis@tarexis.com.